- Home
- ELTX vs CGTX Comparison
ELTX vs CGTX Comparison
Compare ELTX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELTX | CGTX |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELTX | CGTX |
|---|---|---|
| Price | $8.04 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $2.88 |
| AVG Volume (30 Days) | 103.1K | ★ 957.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.60 | $0.22 |
| 52 Week High | $12.62 | $3.83 |
Technical Indicators
Market Signals| Indicator | ELTX | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 43.72 |
| Support Level | $7.89 | $1.37 |
| Resistance Level | $8.32 | $1.62 |
| Average True Range (ATR) | 0.48 | 0.12 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 22.44 | 19.98 |
Price Performance
Historical ComparisonAbout ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.